Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1

Published version of a preprint

Abstract

Despite successes, thus far, a significant proportion of the patients treated with anti-PD1 antibodies have failed to respond. We use mouse tumor models of anti-PD1 sensitivity and resistance and flow cytometry to assess tumor-infiltrating immune cells immediately after therapy. We demonstrate that the expression levels of T-cell PD1 (PD1lo), myeloid, and T-cell PDL1 (PDL1hi) in the tumor microenvironment inversely correlate and dictate the efficacy of anti-PD1 mAb and function of intratumor CD8+ T cells. In sensitive tumors, we reveal a threshold for PD1 downregulation on tumor-infiltrating CD8+ T cells below which the release of adaptive immune resistance is achieved. In contrast, PD1hi T cells in resistant tumors fail to be rescued by anti-PD1 therapy and remain dysfunctional unless intratumor PDL1lo immune cells are targeted. Intratumor Tregs are partly responsible for the development of anti-PD1–resistant tumors and PD1hi CD8+ T cells. Our analyses provide a framework to interrogate intratumor CD8+ T-cell PD1 and immune PDL1 levels and response in human cancer. Cancer Res; 75(18); 3800–11. ©2015 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-15-1082

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

    Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×

    “Anti-CTLA-4 and anti-PD1 are thought to mediate their anti-tumor activity by blocking CTLA-4 or PD1 on effector immune cells (such as CD8 T cells) from interacting with their ligands CD80/CD86 or PDL1/PDL2 (programmed death ligand 1/2), respectively (2,3).”
    Background
  • The blockade of immune checkpoints in cancer immunotherapy

    Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 3×

    “Tumors and immune cells in tumors up regulate PDL1 in response to IFNγ released by TILs as an adaptive immuneresistance mechanism to suppress local effector T-cell function (1), implying that immunosurveillance exists even in advanced cancers.”
    Background
  • Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

    Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 5×

    “13 Discussion By analysing patients treated with anti-human PD1 (pembrolizumab or nivolumab), it has been recently shown that pre-existing intratumor PD1 CD8 T cells, together with the presence of PDL1-expressing cells in the tumor microenvironment, are biomarkers that positively predict response to anti-PD1 mAb thera…”
    BackgroundInfluential
  • Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

    Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · cited 1×

    “In pembrolizumab-treated NSCLC patients, Rizvi and colleagues have recently showed that a higher level of non-synonymous mutation burden in the tumor was associated with improved treatment benefits (28).”
    Background
  • PD-1 blockade induces responses by inhibiting adaptive immune resistance

    Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 4×

    “13 Discussion By analysing patients treated with anti-human PD1 (pembrolizumab or nivolumab), it has been recently shown that pre-existing intratumor PD1 CD8 T cells, together with the presence of PDL1-expressing cells in the tumor microenvironment, are biomarkers that positively predict response to anti-PD1 mAb thera…”
    BackgroundInfluential
  • Nivolumab in Previously Untreated Melanoma without BRAF Mutation

    Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 3×

    “Given the successes of anti-PD1 mAbs in treating patients with melanoma, renal cell carcinoma, non-small cell lung cancer (NSCLC), and Hodgkin’s lymphoma (3-6,12), PD1 levels and frequencies on the intratumor T cells pre- and post-therapy in these patients should now be assessed.”
    Background
  • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×

    “An increased expression of CTLA-4 after anti-PDL1 (MPDL3280A) treatment was also suggested to be a positive predictive biomarker in patients (24).”
    Background
  • Nivolumab plus Ipilimumab in Advanced Melanoma

    Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×

    “We speculate that the synergistic anti-tumor effect observed using the combinations of anti-CTLA-4 (Treg-depleting clones) and anti-PD1 mAbs (16,25); radiotherapy plus anti-CTLA-4/anti-PD1 or antiCD137/anti-PD1 mAbs (15,26) anti-VEGF and anti-PD1 mAbs (27) may be partly mediated through Treg depletion or a disruption…”
    Background
  • PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

    Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560 · cited 3×

    “Given the successes of anti-PD1 mAbs in treating patients with melanoma, renal cell carcinoma, non-small cell lung cancer (NSCLC), and Hodgkin’s lymphoma (3-6,12), PD1 levels and frequencies on the intratumor T cells pre- and post-therapy in these patients should now be assessed.”
    Background
  • Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392 · cited 3×

    “Given the successes of anti-PD1 mAbs in treating patients with melanoma, renal cell carcinoma, non-small cell lung cancer (NSCLC), and Hodgkin’s lymphoma (3-6,12), PD1 levels and frequencies on the intratumor T cells pre- and post-therapy in these patients should now be assessed.”
    Background

Show all 34 references

Cited by

See all 237

Metadata

Authors
Ngiow, S. F., Young, A., Jacquelot, N., Yamazaki, T., Enot, D., Zitvogel, L., & Smyth, M. J.
Affiliations
  • The University of Queensland (AU)
  • Université Paris-Sud (FR)
Venue
Cancer Research
Published
2015-09-14
Volume
75
Issue
18
Pages
3800-3811
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W1915043848
Cited by
237
References
34
Citations by year
2026: 1 · 2025: 19 · 2024: 20 · 2023: 22 · 2022: 21 · 2021: 32 · 2020: 32 · 2019: 22 · 2018: 24 · 2017: 23 · 2016: 18 · 2015: 2
FWCI
9.75
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CD8+ T cells, anti-PD-1 therapy, immune checkpoint inhibitor resistance, tumor-infiltrating lymphocytes, PD-L1 expression, tumor microenvironment, regulatory T cells, adaptive immune resistance, cancer immunotherapy response
MeSH terms
Adenocarcinoma, Animals, Antibodies, Monoclonal, Colonic Neoplasms, Female, Immunization, Passive, Mammary Neoplasms, Experimental, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Neoplasm Proteins, Down-Regulation, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Myeloid Cells, T-Lymphocytes, Regulatory, Mice, Adaptive Immunity, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-1082
The paper
Ngiow, S. F., Young, A., Jacquelot, N., Yamazaki, T., Enot, D., Zitvogel, L., & Smyth, M. J. (2015). A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-1082

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.